Favorable earnings estimate revisions are key for a stock to move higher, precisely where the Zacks Rank comes into play. The Zacks Rank uses four factors related to earnings estimates to classify stocks into five groups, ranging from 'Strong Buy' to 'Strong Sell.' Importantly, it allows individual investors to take advantage of trends in earnings estimate revisions and benefit from the power of institutional investors. Let's examine a few highly ranked stocks, including Stride (LRN) , Interactive Brokers ( ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Develop ...

CARLSBAD, Calif., May 31, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE) demonstrating significant and sustained reduction in mean monthly HAE attack rates and continued attack rate improvement of >90% with one year of treatment for both monthly or every two-month dosing. Patients who switched to donidalorsen from prior prophylactic treatment also sh ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What ar ...

In a shortened week of trading following the Memorial Day weekend, investors may want to take notice of several medical stocks that were added to the Zacks Rank #1 (Strong Buy) list today. Standing out in terms of valuation with earnings estimates on the rise as well, here are three of these highly ranked medical stocks to consider. Haemonetics (HAE) More intriguing is that Lantheus' P/E valuation of 11X looks cheap especially considering FY24 earnings estimates have spiked 8% over the last 30 days while FY ...

Group 1 - MINISO Group Holding Limited (MNSO) has a Zacks Rank 1 with a 12.5% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days [1] - MINISO's shares increased by 22.8% over the last three months, outperforming the S&P 500's 1.1% gain [1] - MINISO possesses a Momentum Score of A [1] Group 2 - Lightspeed Commerce Inc. (LSPD) has a Zacks Rank 1 with a 46.7% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days [2] - Lightspeed's shares gained 7.9% over the last three months, also outperforming the S&P 500's 1.1% gain [2] - Lightspeed possesses a Momentum Score of A [2] Group 3 - Haemonetics Corporation (HAE) has a Zacks Rank 1 with a 7.6% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days [3] - Haemonetics' shares increased by 21% over the last three months, significantly outperforming the S&P 500's 1.1% gain [3] - Haemonetics possesses a Momentum Score of B [3]

In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. Haemonetics (HAE) is on the list of such stocks currently recommended b ...

Core Viewpoint - The article compares Haemonetics (HAE) and Boston Scientific (BSX) to determine which stock offers better value for investors at the current time [1]. Valuation Metrics - HAE has a forward P/E ratio of 19.42, while BSX has a forward P/E of 32.58 [5]. - HAE's PEG ratio is 1.62, indicating a more favorable valuation compared to BSX's PEG ratio of 2.60 [5]. - HAE's P/B ratio stands at 4.67, compared to BSX's P/B of 5.51 [6]. - Based on these valuation metrics, HAE is assigned a Value grade of B, while BSX receives a Value grade of C [6]. Earnings Outlook - Both HAE and BSX currently hold a Zacks Rank of 2 (Buy), indicating an improving earnings outlook due to positive analyst estimate revisions [3]. - The Zacks Rank strategy targets companies with favorable earnings estimate trends, which applies to both HAE and BSX [2]. Investment Recommendation - Based on the analysis of valuation figures and earnings outlook, HAE is considered the superior value option compared to BSX at this time [6].

Haemonetics (HAE) closed the last trading session at $88.64, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $112.20 indicates a 26.6% upside potential. The mean estimate comprises five short-term price targets with a standard deviation of $12.15. While the lowest estimate of $94 indicates a 6.1% increase from the current price level, the most optimistic analyst expect ...

Core Viewpoint - Haemonetics (HAE) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Haemonetics for the fiscal year ending March 2025 is projected at $4.46 per share, reflecting a 12.6% increase from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Haemonetics has risen by 9.8%, indicating a trend of increasing earnings estimates [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 1 places Haemonetics in the top 5% of Zacks-covered stocks, suggesting a strong potential for stock price appreciation in the near term [11]. Market Dynamics - Changes in earnings estimates are strongly correlated with stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [4]. - The Zacks rating system maintains a balanced distribution of 'buy' and 'sell' ratings, ensuring that only the top 20% of stocks are considered for strong recommendations, which enhances the likelihood of market-beating returns [9].